3 February 2020
Consort Medical plc ("the Company")
Additional listing
Application has been made to the
The Shares will rank pari passu with the existing issued Ordinary Shares of the Company, and it is expected that admission to trading in the Shares will become effective on 4 February 2020.
Following the issue of the Shares, the Company will have 49,731,097 Ordinary shares in issue. There are no shares held in treasury.
Enquiries:
Consort Medical |
Tel: +44 (0) 1442 867920 |
Andrew Jackson - Group Counsel and Company Secretary |
|
|
|
About Consort Medical plc
Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.
Our businesses:
Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables and ocular products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.
Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.
We employ approximately 2,000 people globally of which approximately 1,400 are located in the
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the